Mr Julio Gil Onandia

Clinical Trials Assistant

United Kingdom

Julio is a Clinical Trials Assistant for the WOMAN-2 Trial at the CTU Global Health Trials Group in LSHTM. The WOMAN-2 trial looks at the effectiveness of tranexamic acid in reducing postpartum bleeding in anaemic women.

Prior to this, Julio was a Clerical Assistant for the HALTIT Trial that looked at the usage of TXA for the treatment of gastrointestinal bleeding. This trials was also coordinated for the CTU at LSHTM.

Affiliations

Department of Medical Statistics

Faculty of Epidemiology and Population Health

Selected Publications

Alternative routes for tranexamic acid treatment in obstetric bleeding (WOMAN-PharmacoTXA trial): a randomised trial and pharmacological study in caesarean section births.

SHAKUR-STILL, H; ROBERTS, I; Grassin-Delyle, S; Chaudhri, R; GEER, A; ARRIBAS, M; Lamy, E; MANSUKHANI, R; Lubeya, MK; Javaid, K; Kayani, A; Israr, N; Mazhar, SB; Urien, S; Bouazza, N; Foissac, F; Prowse, D; Carrington, L; Barrow, C; ONANDIA, JG; BALOGUN, E;

2023

BJOG : an international journal of obstetrics and gynaecology

Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial.

BRENNER, A; Belli, A; Chaudhri, R; Coats, T; Frimley, L; Jamaluddin, SF; Jooma, R; MANSUKHANI, R; Sandercock, P; SHAKUR-STILL, H; Shokunbi, T; ROBERTS, I; CRASH-3 trial collaborators,;

2020

CRITICAL CARE

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.

HALT-IT Trial Collaborators,;

2020

Lancet (London, England)

Effect of tranexamic acid by baseline risk of death in acute bleeding patients: a meta-analysis of individual patient-level data from 28 333 patients.

AGERON, F-X; Gayet-Ageron, A; Ker, K; Coats, TJ; SHAKUR-STILL, H; Roberts, I; Antifibrinolytics Trials Collaboration,;

2020

BRITISH JOURNAL OF ANAESTHESIA

Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.

CRASH-3 trial collaborators,;